Sharon Mates Sells 20,565 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. (NASDAQ:ITCIGet Free Report) CEO Sharon Mates sold 20,565 shares of Intra-Cellular Therapies stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the completion of the transaction, the chief executive officer now directly owns 1,050,309 shares in the company, valued at $68,490,649.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sharon Mates also recently made the following trade(s):

  • On Thursday, March 7th, Sharon Mates sold 40,712 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $66.50, for a total transaction of $2,707,348.00.
  • On Monday, February 26th, Sharon Mates sold 22,590 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $69.79, for a total transaction of $1,576,556.10.
  • On Tuesday, January 16th, Sharon Mates sold 75,361 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $67.25, for a total transaction of $5,068,027.25.
  • On Thursday, January 18th, Sharon Mates sold 67,917 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $65.19, for a total transaction of $4,427,509.23.

Intra-Cellular Therapies Stock Performance

NASDAQ ITCI traded down $2.05 on Monday, reaching $65.43. 639,068 shares of the company’s stock traded hands, compared to its average volume of 828,147. The firm has a market cap of $6.33 billion, a price-to-earnings ratio of -44.82 and a beta of 1.02. The stock has a 50 day moving average price of $69.32 and a 200-day moving average price of $61.50. Intra-Cellular Therapies, Inc. has a fifty-two week low of $43.18 and a fifty-two week high of $76.11.

Intra-Cellular Therapies (NASDAQ:ITCIGet Free Report) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The company had revenue of $132.10 million during the quarter, compared to analysts’ expectations of $135.97 million. During the same quarter in the previous year, the company earned ($0.45) earnings per share. The firm’s revenue for the quarter was up 50.3% on a year-over-year basis. As a group, equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ITCI has been the subject of several research reports. Robert W. Baird initiated coverage on shares of Intra-Cellular Therapies in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $83.00 price objective for the company. TD Cowen initiated coverage on shares of Intra-Cellular Therapies in a research note on Monday, December 11th. They set an “outperform” rating and a $75.00 price objective for the company. Bank of America lifted their price objective on shares of Intra-Cellular Therapies from $74.00 to $82.00 and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Canaccord Genuity Group lowered their price objective on shares of Intra-Cellular Therapies from $101.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, February 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $101.00 price objective on shares of Intra-Cellular Therapies in a research note on Friday, February 23rd. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $81.42.

Get Our Latest Report on Intra-Cellular Therapies

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Xponance Inc. increased its holdings in Intra-Cellular Therapies by 3.0% in the fourth quarter. Xponance Inc. now owns 5,676 shares of the biopharmaceutical company’s stock valued at $407,000 after buying an additional 163 shares in the last quarter. Metropolitan Life Insurance Co NY increased its stake in shares of Intra-Cellular Therapies by 3.5% during the second quarter. Metropolitan Life Insurance Co NY now owns 5,116 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 175 shares in the last quarter. Regal Investment Advisors LLC increased its stake in shares of Intra-Cellular Therapies by 1.4% during the third quarter. Regal Investment Advisors LLC now owns 13,610 shares of the biopharmaceutical company’s stock worth $709,000 after purchasing an additional 186 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Intra-Cellular Therapies by 0.8% during the third quarter. State Board of Administration of Florida Retirement System now owns 26,796 shares of the biopharmaceutical company’s stock worth $1,396,000 after purchasing an additional 200 shares in the last quarter. Finally, Bailard Inc. increased its stake in shares of Intra-Cellular Therapies by 1.2% during the fourth quarter. Bailard Inc. now owns 17,080 shares of the biopharmaceutical company’s stock worth $1,223,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 86.94% of the company’s stock.

Intra-Cellular Therapies Company Profile

(Get Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Read More

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.